Alpha:
• Mesoblast Limited (NASDAQ:MESO) announces that the FDA has confirmed the receipt of its clinical efficacy and safety data module of its rolling marketing application for cell therapy remestemcel-L for the treatment of children with steroid-refractory acute graft versus host disease, a Fast Track-tagged indication.
• The company expects to file the last module this month with a request for accelerated review. If all goes well, market launch could happen later this year.Alpha: Mesoblast advances remestemcel-L application in U.S.
Ann: MSB Files GvHD Clinical Efficacy and Safety Data with US FDA, page-46
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.176B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | $1.03 | 95.0¢ | $43.38M | 42.28M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 72752 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 205100 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |